Manfred Kranzinger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Manfred Kranzinger has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Felix Sedlmayer
Department of Radiation Oncology, Paracelsus Medical University, SALK, A-5020 Salzburg, Austria
3 shared publications Florian Merz
Salzburg County Hospital, Paracelsus Medical University Clinics
2 shared publications- Franz Zehentmayr
Department of Radiation Oncology, Paracelsus Medical University, A-5020 Salzburg, Austria
2 shared publications - Gerd Fastner
Department of Radiation Oncology, Paracelsus Medical University, 5020 Salzburg, Austria
2 shared publications - Heinz Deutschmann
University Clinic for Radiotherapy and Radio-Oncology, Salzburg, Austria
2 shared publications - Michael Studnicka
University Clinic of Pneumology, Paracelsus Medical University of Salzburg, Salzburg, AUSTRIA
2 shared publications
Latest Publications
- Open Access
- 28 May 2015
- Published by Springer Nature in Radiation Oncology
- Vol. 10 (1) , 121
Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid)
One of the primary dose-limiting toxicities during thoracic irradiation is acute esophagitis (AE). The aim of this study is to investigate dosimetric and clinical predictors for AE grade ≥ 2 in patients treated with accelerated radiotherapy for locally advanced non-small cell lung cancer (NSCLC). 66 NSCLC patients were included in the present analysis: 4 stage II, 44 stage IIIA and 18 stage IIIB. All patients received induction chemotherapy followed by dose differentiated accelerated radiotherapy (DART-bid). Depending on size (mean of three perpendicular diameters) tumors were binned in four dose groups: 6 cm 90 Gy. Patients were treated in 3D target splitting technique. In order to estimate the normal tissue complication probability (NTCP), two Lyman models and the cutoff-logistic regression model were fitted to the data with AE ≥ grade 2 as statistical endpoint. Inter-model comparison was performed with the corrected Akaike information criterion (AICc), which calculates the model’s quality of fit (likelihood value) in relation to its complexity (i.e. number of variables in the model) corrected by the number of patients in the dataset. Toxicity was documented prospectively according to RTOG. The median follow up was 686 days (range 84–2921 days), 23/66 patients (35 %) experienced AE ≥ grade 2. The actuarial local control rates were 72.6 % and 59.4 % at 2 and 3 years, regional control was 91 % at both time points. The Lyman-MED model (D50 = 32.8 Gy, m = 0.48) and the cutoff dose model (Dc = 38 Gy) provide the most efficient fit to the current dataset. On multivariate analysis V38 (volume of the esophagus that receives 38 Gy or above, 95 %-CI 28.2–57.3) was the most significant predictor of AE ≥ grade 2 (HR = 1.05, CI 1.01–1.09, p = 0.007). Following high-dose accelerated radiotherapy the rate of AE ≥ grade 2 is slightly lower than reported for concomitant radio-chemotherapy with the additional benefit of markedly increased loco-regional tumor control. In the current patient cohort the most significant predictor of AE was found to be V38. A second clinically useful parameter in treatment planning may be MED (mean esophageal dose).
- 28 May 2015
- Published by Springer Nature in Radiation Oncology
- Vol. 10 (1) , 121
Open AccessNormal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid)
One of the primary dose-limiting toxicities during thoracic irradiation is acute esophagitis (AE). The aim of this study is to investigate dosimetric and clinical predictors for AE grade ≥ 2 in patients treated with accelerated radiotherapy for locally advanced non-small cell lung cancer (NSCLC). 66 NSCLC patients were included in the present analysis: 4 stage II, 44 stage IIIA and 18 stage IIIB. All patients received induction chemotherapy followed by dose differentiated accelerated radiotherapy (DART-bid). Depending on size (mean of three perpendicular diameters) tumors were binned in four dose groups: 6 cm 90 Gy. Patients were treated in 3D target splitting technique. In order to estimate the normal tissue complication probability (NTCP), two Lyman models and the cutoff-logistic regression model were fitted to the data with AE ≥ grade 2 as statistical endpoint. Inter-model comparison was performed with the corrected Akaike information criterion (AICc), which calculates the model’s quality of fit (likelihood value) in relation to its complexity (i.e. number of variables in the model) corrected by the number of patients in the dataset. Toxicity was documented prospectively according to RTOG. The median follow up was 686 days (range 84–2921 days), 23/66 patients (35 %) experienced AE ≥ grade 2. The actuarial local control rates were 72.6 % and 59.4 % at 2 and 3 years, regional control was 91 % at both time points. The Lyman-MED model (D50 = 32.8 Gy, m = 0.48) and the cutoff dose model (Dc = 38 Gy) provide the most efficient fit to the current dataset. On multivariate analysis V38 (volume of the esophagus that receives 38 Gy or above, 95 %-CI 28.2–57.3) was the most significant predictor of AE ≥ grade 2 (HR = 1.05, CI 1.01–1.09, p = 0.007). Following high-dose accelerated radiotherapy the rate of AE ≥ grade 2 is slightly lower than reported for concomitant radio-chemotherapy with the additional benefit of markedly increased loco-regional tumor control. In the current patient cohort the most significant predictor of AE was found to be V38. A second clinically useful parameter in treatment planning may be MED (mean esophageal dose).
- 18 March 2014
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 190 (9) , 798-805
Hypofractionated stereotactic radiotherapy of acoustic neuroma
The goal of this work was to evaluate toxicity and local control following hypofractionated stereotactic radiation treatment with special focus on changes in tumor volume and hearing capacity. In all, 29 patients with unilateral acoustic neuroma were treated between 2001 and 2007 within a prospective radiation protocol (7 × 4 Gy ICRU dose). Median tumor volume was 0.9 ml. Follow-up started at 6 months and was repeated annually with MRI volumetry and audiometry. Hearing preservation was defined as preservation of Class A/B hearing according to the guidelines of the American Academy of Otolaryngology (1995). No patient had any intervention after a median imaging follow-up of 89.5 months, one patient showed radiological progression. Transient increase of tumor volume developed in 17/29 patients, whereas 22/29 patients (75.9 %) presented with a volume reduction at last follow-up. A total of 21 patients were eligible for hearing evaluation. Mean pure tone average (PTA) deteriorated from 39.3 to 65.9 dB and mean speech discrimination score (SDS) dropped from 74.3 to 38.1 %. The 5-year actuarial Class A/B hearing preservation rate was 50.0 ± 14.4 %. Radiation increases only minimally, if at all, the hearing deterioration which emerges by observation alone. Presbyacusis is not responsible for this deterioration. Transient tumor enlargement is common. Today radiation of small- and medium-sized acoustic neuroma can be performed with different highly conformal techniques as fractionated treatment or single low-dose radiosurgery with equal results regarding tumor control, hearing preservation, and side effects. Hypofractionation is more comfortable for the patient than conventional regimens and represents a serious alternative to frameless radiosurgery. Ziel der Studie war die Evaluierung der Toxizität und der lokalen Tumorkontrolle einer hypofraktionierten stereotaktischen Bestrahlung mit besonderem Augenmerk auf Veränderungen von Tumorvolumen und Hörvermögen. Insgesamt wurden zwischen 2001 und 2007 29 Patienten mit unilateralem Akustikusneurinom innerhalb eines prospektiven Bestrahlungsprotokolls behandelt (7 mal 4 Gy ICRU-Dosis). Das mediane Tumorvolumen betrug 0,9 ml. Die Nachsorge startete nach 6 Monaten und wurde jährlich wiederholt mit MRI-Volumetrie und Audiometrie. Der Hörerhalt wurde definiert als Erhalt eines Class-A/B-Hörvermögens nach den Richtlinien der American Academy of Otolaryngology (1995). Kein Patient benötigte eine Intervention nach einer medianen Nachbeobachtungszeit von 89,5 Monaten, ein Patient entwickelte eine radiologische Progression. Eine vorübergehende Volumenzunahme zeigte sich bei 17/29 Patienten nach 6 Monaten, eine Volumenreduktion wiesen 22/29 Patienten (75,9 %) bei der jüngsten Nachsorgeuntersuchung auf. Insgesamt waren 21 Patienten bezüglich des Hörerhalts auswertbar. Der Mittelwert im Tonaudiogramm (PTA) verschlechterte sich von 39,3 dB auf 65,9 dB, das durchschnittliche Sprachverständnis (SDS) fiel von 74,3 % auf 38,1 %. Der aktuarische 5-Jahres-Class-A/B-Hörerhalt betrug 50,0 ± 14,4 %. Der Grad der Hörminderung nach Bestrahlung ist, wenn überhaupt, nur minimal deutlicher als nach alleiniger Beobachtung. Presbyakusis ist nicht verantwortlich für diese zunehmende Hypakusis. Eine vorübergehende Volumenzunahme ist häufig. Heute ist eine Bestrahlung von kleinen bis mittelgroßen Akustikusneurinomen mit jeder hochkonformalen Technik als fraktionierte oder niedrigdosierte singuläre Behandlung mit gleichwertigem Ergebnis bezüglich Tumorkontrolle, Hörerhalt und Nebenwirkungen durchführbar. Die hypofraktionierte Bestrahlung ist für den Patienten komfortabler als konventionelle Schemata und eine ernsthafte Alternative zur nichtinvasiven Radiochirurgie.
- 18 March 2014
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 190 (9) , 798-805
Hypofractionated stereotactic radiotherapy of acoustic neuroma
The goal of this work was to evaluate toxicity and local control following hypofractionated stereotactic radiation treatment with special focus on changes in tumor volume and hearing capacity. In all, 29 patients with unilateral acoustic neuroma were treated between 2001 and 2007 within a prospective radiation protocol (7 × 4 Gy ICRU dose). Median tumor volume was 0.9 ml. Follow-up started at 6 months and was repeated annually with MRI volumetry and audiometry. Hearing preservation was defined as preservation of Class A/B hearing according to the guidelines of the American Academy of Otolaryngology (1995). No patient had any intervention after a median imaging follow-up of 89.5 months, one patient showed radiological progression. Transient increase of tumor volume developed in 17/29 patients, whereas 22/29 patients (75.9 %) presented with a volume reduction at last follow-up. A total of 21 patients were eligible for hearing evaluation. Mean pure tone average (PTA) deteriorated from 39.3 to 65.9 dB and mean speech discrimination score (SDS) dropped from 74.3 to 38.1 %. The 5-year actuarial Class A/B hearing preservation rate was 50.0 ± 14.4 %. Radiation increases only minimally, if at all, the hearing deterioration which emerges by observation alone. Presbyacusis is not responsible for this deterioration. Transient tumor enlargement is common. Today radiation of small- and medium-sized acoustic neuroma can be performed with different highly conformal techniques as fractionated treatment or single low-dose radiosurgery with equal results regarding tumor control, hearing preservation, and side effects. Hypofractionation is more comfortable for the patient than conventional regimens and represents a serious alternative to frameless radiosurgery. Ziel der Studie war die Evaluierung der Toxizität und der lokalen Tumorkontrolle einer hypofraktionierten stereotaktischen Bestrahlung mit besonderem Augenmerk auf Veränderungen von Tumorvolumen und Hörvermögen. Insgesamt wurden zwischen 2001 und 2007 29 Patienten mit unilateralem Akustikusneurinom innerhalb eines prospektiven Bestrahlungsprotokolls behandelt (7 mal 4 Gy ICRU-Dosis). Das mediane Tumorvolumen betrug 0,9 ml. Die Nachsorge startete nach 6 Monaten und wurde jährlich wiederholt mit MRI-Volumetrie und Audiometrie. Der Hörerhalt wurde definiert als Erhalt eines Class-A/B-Hörvermögens nach den Richtlinien der American Academy of Otolaryngology (1995). Kein Patient benötigte eine Intervention nach einer medianen Nachbeobachtungszeit von 89,5 Monaten, ein Patient entwickelte eine radiologische Progression. Eine vorübergehende Volumenzunahme zeigte sich bei 17/29 Patienten nach 6 Monaten, eine Volumenreduktion wiesen 22/29 Patienten (75,9 %) bei der jüngsten Nachsorgeuntersuchung auf. Insgesamt waren 21 Patienten bezüglich des Hörerhalts auswertbar. Der Mittelwert im Tonaudiogramm (PTA) verschlechterte sich von 39,3 dB auf 65,9 dB, das durchschnittliche Sprachverständnis (SDS) fiel von 74,3 % auf 38,1 %. Der aktuarische 5-Jahres-Class-A/B-Hörerhalt betrug 50,0 ± 14,4 %. Der Grad der Hörminderung nach Bestrahlung ist, wenn überhaupt, nur minimal deutlicher als nach alleiniger Beobachtung. Presbyakusis ist nicht verantwortlich für diese zunehmende Hypakusis. Eine vorübergehende Volumenzunahme ist häufig. Heute ist eine Bestrahlung von kleinen bis mittelgroßen Akustikusneurinomen mit jeder hochkonformalen Technik als fraktionierte oder niedrigdosierte singuläre Behandlung mit gleichwertigem Ergebnis bezüglich Tumorkontrolle, Hörerhalt und Nebenwirkungen durchführbar. Die hypofraktionierte Bestrahlung ist für den Patienten komfortabler als konventionelle Schemata und eine ernsthafte Alternative zur nichtinvasiven Radiochirurgie.